Drug observers puzzled by vaccine maker, which made a killing on COVID-19, failing to read the room with new administration. Moderna puts heat on FDA vaccines chief who's already been rebuked once by ...
The FDA declined to review Moderna's mRNA influenza vaccine due to inadequate clinical trial comparators for older adults.
The rejection of Disc Medicine Inc.’s experimental compound for a rare and devastating disorder by the US Food and Drug Administration, just months after it received a voucher intended to speed US ...
Moby Strategic Execution and Operational Pivot. Achieved a significant financial turning point in 2025 by reducing operating expenses ...
Moderna posts a fourth-quarter loss of $2.11 a share on revenue of $678 million.
Moderna (NASDAQ:MRNA) is escalating its standoff with US regulators at a delicate juncture in its post-pandemic reset. On Friday's analyst call, Chief Executive Officer Stephane Bancel described the ...
FDA Refuses To Review Moderna mRNA Flu Vaccine and the US Could Miss Out on Next Generation Fu Shots
In a rare and surprising move, the FDA has issued a “Refusal to File” letter for Moderna’s mRNA-1010 influenza vaccine.
After a string of high-profile regulatory rebukes, Biohaven’s CEO believes red tape is getting in the way of patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results